Beyond Air Posts 105% Revenue Growth, Secures $32.5M NeuroNOS Deal
Event summary
- Beyond Air reported a 105% year-over-year revenue increase to $2.2M in Q3 2026, driven by LungFit PH demand.
- XTL Biopharmaceuticals agreed to acquire 85% of NeuroNOS for up to $32.5M, including $1M upfront and $31.5M in milestones.
- Phase 1a data from the UNO solid tumor program will be presented at the AACR Annual Meeting in April 2026.
- Pro forma cash position stands at $22.3M, providing runway into 2027.
The big picture
Beyond Air's revenue surge reflects growing adoption of its nitric oxide delivery system, while the NeuroNOS deal signals a strategic pivot toward neuro-oncology. The company's ability to sustain momentum hinges on regulatory approvals and clinical trial outcomes, as it competes in a crowded medical device and biopharma landscape. With $22.3M in cash, Beyond Air has runway to execute its growth plans, but must demonstrate commercial scalability to justify its valuation.
What we're watching
- Regulatory Timing
- Whether Beyond Air secures FDA clearance for its second-generation LungFit PH system by year-end 2026.
- Commercial Expansion
- The pace at which LungFit PH gains traction in the VA system and international markets.
- Clinical Progress
- How Phase 1a UNO data impacts investor sentiment ahead of potential Phase 1b trials.
Related topics